Publications by authors named "Aya Ryuzoji"

Article Synopsis
  • IL-13 is a key cytokine involved in the pathophysiology of atopic dermatitis (AD), and lebrikizumab, tralokinumab, and cendakimab are monoclonal antibodies designed to target this cytokine.
  • Studies showed that lebrikizumab has a higher affinity for IL-13 and is more effective in neutralizing its effects than the other two antibodies, based on various assays and imaging techniques.
  • Unlike tralokinumab and cendakimab, lebrikizumab allows for the internalization of the IL-13 complex into cells, suggesting a unique mechanism that may explain its increased clinical effectiveness in treating AD.
View Article and Find Full Text PDF

Product- and process- related critical quality attributes have the potential to impact pharmacokinetics, immunogenicity, potency, and safety of biotherapeutics. Among these critical quality attributes are chemical degradations, specifically oxidation, deamidation, and isomerization. These degradations can be induced by stressors such as light, pH, or temperature; they can also occur naturally under normal conditions.

View Article and Find Full Text PDF

Activation of the transcription factor Nrf2 has been posited to be a promising therapeutic strategy in a number of inflammatory and oxidative stress diseases due to its regulation of detoxifying enzymes. In this work, we have developed a comprehensive structure-activity relationship around a known, naphthalene-based non-electrophilic activator of Nrf2, and we report highly potent non-electrophilic activators of Nrf2. Computational docking analysis of a subset of the compound series demonstrates the importance of water molecule displacement for affinity, and the X-ray structure of di-amide 12e supports the computational analysis.

View Article and Find Full Text PDF